Manuscript
Precision prescribing of SGLT2-inhibitors in people with type 2 diabetes for primary prevention of heart failure: model development and validation study
Katherine G Young et al.
Diabetes Care 2026;49:1115-1123
Manuscript
Serial Assessment of NT-proBNP and High-Sensitivity Cardiac Troponin with Glucagon-Like Peptide-1 Receptor Agonist Therapy in Type 2 Diabetes: Insights from EXSCEL
Veraprapas Kittipibul et al.
Am Heart J. 2026
Manuscript
CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum
Oliver Schnell et al.
Cardiovasc Diabetol. 2026;25:142
Manuscript
Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists
Mahesh M Umapathysivam et al.
Genome Med. 2026
Manuscript
Worsening Kidney Function and Cardiovascular Outcomes in Type 2 Diabetes and Atherosclerotic Disease
Abhinav Sharma et al.
JACC Adv. 2026;5:102598
Manuscript
Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study
Laura M. Güdemann et al.
The Lancet Regional Health – Europe 2026;61:101547